UBS analyst AJ Rice lowered the firm’s price target on Pediatrix Medical (MD) to $16 from $18.50 and keeps a Neutral rating on the shares. 2025 is starting out strong for Pediatrix, and capital deployment remains a focus, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical Group Holds Annual Shareholders’ Meeting
- Hold Rating on Pediatrix Medical Group Amid Uncertain Birth Trends and Payer Mix Shifts
- Pediatrix Medical Group Reports Strong Q1 Earnings
- Pediatrix Medical Group’s Optimistic Q1 Earnings Call
- Pediatrix Medical reports Q1 adjusted EPS 33c, consensus 24c